Showing 1086 results
-
Press release /Multicenter survey results show MS patients and nurses prefer the Sensoready autoinjector pen for subcutaneous self-administration of Kesimpta over other autoinjectors for their current treatment (84…
-
Press release /Two-year efficacy and safety data analyses from Phase III SUNSHINE and SUNRISE trials of continuous Cosentyx® (secukinumab) treatment in HS to be presentedNew analyses of 52-week data from Phase III…
-
Press release /
Novartis to highlight Rhapsido® data across multiple immune-mediated diseases at EAACI Congress 2026
Results from Rhapsido (remibrutinib) pivotal Phase III RemIND trial, the largest study in chronic inducible urticaria, to be highlighted in late-breaker oral presentationNew Phase IIIb REMIXED… -
Press release /FY net sales (0% cc[2]) in line with prior year due to strong Growth Products performance Cosentyx (USD 1.1 billion) reached blockbuster status Entresto (USD 170 million) continued to grow…
-
Press release /Sales, core[1] operating income and core EPS grew (cc[1]) for continuing operations[2] in Q2: Net sales amounted to USD 12.7 billion (-5%, +6% cc) Operating income was USD 2.3…
-
Ad hoc release /Annonce événementielle au sens de l’art. 53 RCExercice complet (activités poursuivies2)Hausse de +10 % (tcc, +8 % USD) du chiffre d’affaires net et de +18 % (tcc, +11 % USD) du…
-
Press release /Heads-up design using high definition 3D screen engineered to improve surgeons posture and may reduce fatigue[1] Offers enhanced 3D visualization with high-definition resolution, image…
-
Press release /The European Commission approved Lucentis to treat patients for visual impairment due to choroidal neovascularization (CNV) associated with causes other than neovascular age-related macular…
-
Press release /US Food and Drug Administration (FDA) grants approval for CyPass Micro-Stent for sale in the US, expanding Alcon's surgical presence to treat glaucoma The CyPass Micro-Stent is designed to…